{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T12:27:16Z","timestamp":1772886436140,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.intimp.2020.107099","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T13:58:24Z","timestamp":1603115904000},"page":"107099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"PB","title":["Bifunctional macromolecule activating both OX40 and interferon-\u03b1 signaling displays potent therapeutic effects in mouse HBV and tumor models"],"prefix":"10.1016","volume":"89","author":[{"given":"Shifu","family":"Mo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhichao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingdong","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2020.107099_b0005","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1146\/annurev.bi.56.070187.003455","article-title":"Interferons and their actions","volume":"56","author":"Pestka","year":"1987","journal-title":"Annu. Rev. Biochem."},{"issue":"4","key":"10.1016\/j.intimp.2020.107099_b0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cytogfr.2014.07.015","article-title":"Interferons: success in anti-viral immunotherapy","volume":"25","author":"Lin","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"issue":"3","key":"10.1016\/j.intimp.2020.107099_b0015","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1053\/j.seminoncol.2015.02.012","article-title":"Immune checkpoint blockade and interferon-alpha in melanoma","volume":"42","author":"Rafique","year":"2015","journal-title":"Semin. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2020.107099_b0020","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"issue":"5 Suppl","key":"10.1016\/j.intimp.2020.107099_b0025","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1002\/hep.22956","article-title":"Benefits and risks of interferon therapy for hepatitis B","volume":"49","author":"Perrillo","year":"2009","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.intimp.2020.107099_b0030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bpg.2017.04.012","article-title":"Current treatment guidelines of chronic hepatitis B: the role of nucleos(t)ide analogues and peginterferon","volume":"31","author":"Ghany","year":"2017","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2020.107099_b0035","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/liv.13635","article-title":"Treatment of hepatitis B: Is there still a role for interferon?","volume":"38","author":"Vigano","year":"2018","journal-title":"Liver Int.: Off. J. Int. Assoc. Study Liver"},{"issue":"1","key":"10.1016\/j.intimp.2020.107099_b0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.14218\/JCTH.2017.00072","article-title":"HBsAg loss with Peg-interferon Alfa-2a in Hepatitis B patients with partial response to nucleos(t)ide analog: new switch study","volume":"6","author":"Hu","year":"2018","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"8","key":"10.1016\/j.intimp.2020.107099_b0045","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/jvh.12691","article-title":"Hepatitis B surface antigen reduction by switching from long-term nucleoside\/nucleotide analogue administration to pegylated interferon","volume":"24","author":"Tamaki","year":"2017","journal-title":"J. Viral Hepatitis"},{"issue":"4","key":"10.1016\/j.intimp.2020.107099_b0050","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/apt.15098","article-title":"Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B","volume":"49","author":"Liem","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"26","key":"10.1016\/j.intimp.2020.107099_b0055","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"New England J. Med."},{"issue":"9454","key":"10.1016\/j.intimp.2020.107099_b0060","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.intimp.2020.107099_b0065","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"New England J. Med."},{"key":"10.1016\/j.intimp.2020.107099_b0070","article-title":"RNA interference therapy with ARC-520 results in prolonged HBsAg response in patients with chronic hepatitis B infection","author":"Yuen","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.intimp.2020.107099_b0075","unstructured":"E.J.L.S. Gane, T.H. Lim et al., First results with RNA interference (RNAi) in chronic hepatitis B (CHB) using ARO-HBV, in: The Liver Meeting: November 9\u201313, San Francisco, CA, 2018."},{"key":"10.1016\/j.intimp.2020.107099_b0080","unstructured":"E.J.L.S. Gane, T.H. Lim et al., RNA interference (RNAi) in chronic hepatitis B (CHB): data from phase 2 study with JNJ-3989, in: 28th annual Conference of the Asian Pacific Association for the Study of the Liver: February 20\u201324; Manila, Philippines, 2019."},{"issue":"3","key":"10.1016\/j.intimp.2020.107099_b0085","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cld.2019.04.006","article-title":"Drugs in the Pipeline for HBV","volume":"23","author":"Lopatin","year":"2019","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.intimp.2020.107099_b0090","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2015.08.021","article-title":"Rationale for anti-OX40 cancer immunotherapy","volume":"52","author":"Aspeslagh","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2020.107099_b0095","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.4049\/jimmunol.172.8.4821","article-title":"Costimulation of CD8 T cell responses by OX40","volume":"172","author":"Bansal-Pakala","year":"2004","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2020.107099_b0100","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1074-7613(01)00191-1","article-title":"OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells","volume":"15","author":"Rogers","year":"2001","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.intimp.2020.107099_b0105","doi-asserted-by":"crossref","first-page":"e70635","DOI":"10.1371\/journal.pone.0070635","article-title":"Regulation of A1 by OX40 contributes to CD8(+) T cell survival and anti-tumor activity","volume":"8","author":"Lei","year":"2013","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.intimp.2020.107099_b0110","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.4049\/jimmunol.164.4.2160","article-title":"Engagement of the OX-40 receptor in vivo enhances antitumor immunity","volume":"164","author":"Weinberg","year":"2000","journal-title":"J. Immunol."},{"issue":"19","key":"10.1016\/j.intimp.2020.107099_b0115","first-page":"5514","article-title":"Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth","volume":"60","author":"Kjaergaard","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2020.107099_b0120","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fonc.2015.00034","article-title":"OX40 Agonists and combination immunotherapy: putting the pedal to the metal","volume":"5","author":"Linch","year":"2015","journal-title":"Front. Oncol."},{"issue":"433","key":"10.1016\/j.intimp.2020.107099_b0125","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah5766","article-title":"Mansfield KG et al.: An OX40\/OX40L interaction directs successful immunity to hepatitis B virus","volume":"10","author":"Publicover","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.intimp.2020.107099_b0130","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jhep.2019.02.016","article-title":"OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection","volume":"70","author":"Jacobi","year":"2019","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.intimp.2020.107099_b0135","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4049\/jimmunol.1102550","article-title":"Type I IFN-dependent T cell activation is mediated by IFN-dependent dendritic cell OX40 ligand expression and is independent of T cell IFNR expression","volume":"188","author":"Kurche","year":"2012","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2020.107099_b0140","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","article-title":"The significance of OX40 and OX40L to T-cell biology and immune disease","volume":"229","author":"Croft","year":"2009","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.intimp.2020.107099_b0145","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.4049\/jimmunol.165.6.3043","article-title":"The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion","volume":"165","author":"Gramaglia","year":"2000","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2020.107099_b0150","doi-asserted-by":"crossref","first-page":"5990","DOI":"10.4049\/jimmunol.181.9.5990","article-title":"OX40 costimulatory signals potentiate the memory commitment of effector CD8+ T cells","volume":"181","author":"Mousavi","year":"2008","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2020.107099_b0155","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/14712598.2017.1289169","article-title":"Role of interferon in melanoma: old hopes and new perspectives","volume":"17","author":"Sanlorenzo","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"issue":"8","key":"10.1016\/j.intimp.2020.107099_b0160","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.it.2017.05.005","article-title":"Type I interferon in chronic virus infection and cancer","volume":"38","author":"Snell","year":"2017","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2020.107099_b0165","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000573","article-title":"New pathways in immune stimulation: targeting OX40","volume":"5","author":"Alves Costa Silva","year":"2020","journal-title":"ESMO Open"},{"issue":"24","key":"10.1016\/j.intimp.2020.107099_b0170","doi-asserted-by":"crossref","first-page":"13269","DOI":"10.1073\/pnas.230429197","article-title":"Functional cooperation between T helper cell determinants","volume":"97","author":"Gerloni","year":"2000","journal-title":"PNAS"},{"issue":"8","key":"10.1016\/j.intimp.2020.107099_b0175","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/eji.1830260805","article-title":"OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand","volume":"26","author":"al-Shamkhani","year":"1996","journal-title":"Eur. J. Immunol."},{"issue":"47","key":"10.1016\/j.intimp.2020.107099_b0180","doi-asserted-by":"crossref","first-page":"17862","DOI":"10.1073\/pnas.0608578103","article-title":"An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection","volume":"103","author":"Huang","year":"2006","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2020.107099_b0185","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3389\/fimmu.2018.00219","article-title":"Hepatitis B virus-specific CD8+ T cells maintain functional exhaustion after antigen reexposure in an acute activation immune environment","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Immunol."},{"issue":"21","key":"10.1016\/j.intimp.2020.107099_b0190","doi-asserted-by":"crossref","first-page":"13825","DOI":"10.1073\/pnas.202398599","article-title":"Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection","volume":"99","author":"Yang","year":"2002","journal-title":"PNAS"},{"issue":"3","key":"10.1016\/j.intimp.2020.107099_b0195","doi-asserted-by":"crossref","first-page":"e90977","DOI":"10.1371\/journal.pone.0090977","article-title":"Susceptibility of different hepatitis B virus isolates to interferon-alpha in a mouse model based on hydrodynamic injection","volume":"9","author":"Song","year":"2014","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.intimp.2020.107099_b0200","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1021\/bc049713n","article-title":"A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation","volume":"16","author":"Rosendahl","year":"2005","journal-title":"Bioconjug. Chem."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2020.107099_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2011.03.005","article-title":"Mouse blood monocytes: standardizing their identification and analysis using CD115","volume":"390","author":"Breslin","year":"2013","journal-title":"J. Immunol. Methods"},{"issue":"5","key":"10.1016\/j.intimp.2020.107099_b0210","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.2353\/ajpath.2009.090328","article-title":"Type I interferon modulates monocyte recruitment and maturation in chronic inflammation","volume":"175","author":"Lee","year":"2009","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.intimp.2020.107099_b0215","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41598-017-00469-1","article-title":"Different antiviral effects of IFNalpha subtypes in a mouse model of HBV infection","volume":"7","author":"Song","year":"2017","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.intimp.2020.107099_b0220","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.4049\/jimmunol.1202752","article-title":"Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function","volume":"191","author":"Voo","year":"2013","journal-title":"J. Immunol."},{"issue":"426","key":"10.1016\/j.intimp.2020.107099_b0225","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan4488","article-title":"Eradication of spontaneous malignancy by local immunotherapy","volume":"10","author":"Sagiv-Barfi","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.intimp.2020.107099_b0230","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1002\/1521-4141(200212)32:12<3617::AID-IMMU3617>3.0.CO;2-M","article-title":"Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4\u20131BB), and their role in the generation of anti-tumor immune responses","volume":"32","author":"Taraban","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2020.107099_b0235","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ebiom.2018.11.062","article-title":"Concomitant type I IFN and M-CSF signaling reprograms monocyte differentiation and drives pro-tumoral arginase production","volume":"39","author":"Tong","year":"2019","journal-title":"EBioMedicine"},{"issue":"10","key":"10.1016\/j.intimp.2020.107099_b0240","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1172\/JCI127458","article-title":"Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation","volume":"129","author":"Chen","year":"2019","journal-title":"J. Clin. Investig."},{"issue":"10","key":"10.1016\/j.intimp.2020.107099_b0245","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s41422-019-0224-x","article-title":"Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade","volume":"29","author":"Jacquelot","year":"2019","journal-title":"Cell Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920326801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920326801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:20:32Z","timestamp":1761585632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920326801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":49,"alternative-id":["S1567576920326801"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.107099","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bifunctional macromolecule activating both OX40 and interferon-\u03b1 signaling displays potent therapeutic effects in mouse HBV and tumor models","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.107099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107099"}}